Expected events to wind up the third quarter | Biotech Message Board Posts
  • TECH UPDATE: Please accept our apologies for the delay in getting our "board visit & message view" counts to normalize. As you may have noticed, starting yesterday the "board stats" for individual message boards started to display clearly erroneous "member" and "guest" visit counts. Needless to say, we don't like having unreliable traffic stats on the site any more than you do. Please understand this was not by design or intention. It's a glitch that resulted from an apparent incompatibility with the legacy code and the recent deployment of new servers to tackle issues related to last month's outage. In order to give our web developer a chance to take a closer look at the glitch and come up with a viable solution, we have decided to leave the code up for now so she can have real-world data to work with (rather than just turn the counts off again). So it looks like we may have to live with these bad counts a little longer, but our expectation is to have this resolved by early next week, if not sooner. We appreciate your patience and understanding.  

Biotech   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34535 of 34886  at  9/26/2020 1:09:38 PM  by

Cougar3


Expected events to wind up the third quarter

 
 
Drug Stage Catalyst Market Cap

ASND – Ascendis Pharma A/S

TransCon

Hypoparathyroidism

Phase 2 Phase 2 six-month data from the open-label extension portion due 3Q 2020. Phase 3 trial to commence 4Q 2020.
$8.2 billion

CYCN – Cyclerion Therapeutics Inc.

Olinciguat (IW-1701) - STRONG-SCD

Sickle Cell disease

Phase 2 Phase 2 data due late-3Q 2020.
$230.7 million

CYCN – Cyclerion Therapeutics Inc.

IW-6463

Healthy volunteers

Phase 1 Phase 1 translational pharmacology top-line data due September 2020.
$230.7 million

ETON – Eton Pharmaceuticals Inc.

Alkindi Sprinkle

Pediatric adrenal insufficiency (AI)

PDUFA PDUFA date September 29, 2020.
$173.5 million

FIXX – Homology Medicines Inc.

HMI-102

Phenylketonuria (PKU)

Phase 1/2 Phase 1/2 update due 3Q/4Q 2020.
$498.1 million

MESO – Mesoblast Limited

Remestemcel-L (MSC-100-IV)

acute graft versus host disease (aGVHD) in children

PDUFA priority review PDUFA date under priority review September 30, 2020. FDA Oncologic Drugs Advisory Committee meeting August 13, 2020 voted 8-2 supporting approval.
$2.1 billion

MYOV – Myovant Sciences Ltd.

Relugolix

Advanced prostate cancer

Phase 3 PDUFA date under priority review December 20, 2020. Castration Resistance Free Survival data due 3Q 2020.
$1.9 billion

OVID – Ovid Therapeutics Inc.

TAK-935/OV935 - ARCADE

CDKL5 Deficiency

Phase 2 Phase 2 data due 3Q 2020.
$368.9 million

REGN – Regeneron Pharmaceuticals Inc.

REGN-COV2

COVID-19 (Anti-viral antibody)

Phase 2/3 Phase 2/3 trial has been initiated. Initial virology and biomarker data due September 2020.
$61.1 billion

SELB – Selecta Biosciences Inc.

SEL-212 (COMPARE) - Head to head trial vs Krystexxa

Tophaceous gout

Phase 2Phase 2 top-line data due 3Q 2020.
$259.3 million


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 8     Views: 282
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.
Loading...